Palisade Bio (NASDAQ:PALI) Earns “Buy” Rating from Maxim Group

Palisade Bio (NASDAQ:PALI)‘s stock had its “buy” rating reiterated by investment analysts at Maxim Group in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $22.50 price target on the stock. Maxim Group’s target price would suggest a potential upside of 211.63% from the company’s previous close.

Palisade Bio Price Performance

NASDAQ PALI traded up $1.19 during mid-day trading on Wednesday, hitting $7.22. The company’s stock had a trading volume of 11,770,327 shares, compared to its average volume of 942,198. The firm has a market capitalization of $6.14 million, a P/E ratio of -0.27 and a beta of 1.33. The stock’s fifty day simple moving average is $5.70 and its two-hundred day simple moving average is $7.47. Palisade Bio has a 52-week low of $3.82 and a 52-week high of $36.60.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($3.75) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Palisade Bio will post -12.29 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.